Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Paris Steps Up in Life Sciences <em>(CF News)</em>

main

04_21 Goodwin Paris Steps Up in Life Sciences

Goodwin has recruited Anne-Charlotte Rivière as a partner in Paris in order to form a venture division dedicated to Life Sciences and Technologies.

Goodwin Paris Steps Up in Life Sciences (CF News)

Related Content

Delaware Creates More Corporate Clarity and Overhauls Rules Governing Conflicted Transactions

Medtech M&A and VC Signal Positive Momentum Entering 2025

2025 HSR Thresholds Announced: $126.4 million

Business Groups File Lawsuit Challenging HSR Rule Changes

The Rapid Rise of AI, in Five Charts

How Fund Terms and Approaches Vary by Asset Class, in Four Charts

Which Jobs More Frequently Require Non-Compete Agreements?

FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements

Goodwin Advises Sonocharge Energy on $23.5 Million Series A Financing, with Participation from Cycle Capital, Honda, and Current Investors Khosla Ventures and Temasek

The Legal 500 EMEA 2025 Recognizes Goodwin for Excellence Across Europe

Goodwin Advises Equilibrium Energy on $28 Million Series B2 Funding

Goodwin Leads M&A, Private Equity, and Venture Capital League Table Rankings for 2024

Goodwin Paris Recognized by Chambers France 2025

Goodwin Advises Ouro Medicines on its $120 Million Launch and In-License for Keymed’s Novel T-Cell Engager

Daniel Isaacs Named a 2025 Rising Star by Venture Capital Journal

Goodwin is Number One Globally for Venture Capital and Private Equity in Q3 2024

Private Equity

Life Sciences

Technology

Medtech

Venture Capital

Mergers & Acquisitions

Private Equity France

Life Sciences Europe

Technology Europe